Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Merger or Acquisition (August 2014)
19 slides from Actinogen Medical's merger presentation, Aug 27, 2014
Slide 1: Acquisition of Corticrine Ltd, A UK Dementia Company
For personal use only Actinogen Ltd ACQUISITION OF Corticrine Ltd A UK DEMENTIA COMPANY Today, someone in North America develops Alzheimer’s Disease every 68 seconds. By 2050, there is expected to be one new case of AD every 33 seconds
Slide 2: Important Information
This presentation has been prepared by Actinogen Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment dec
Slide 3: Corporate Overview and Acquisition Breakdown
Corporate Overview Acquisition Breakdown ASX Code: ACW Actinogen Ltd Corticrine Ltd Share Price: $0.02 For personal use only Shares 202.6m 125m Market cap: $8.6m Cash: $3.0m Options 54m @ 2c Post Acquisition Shares on issue: Options: 427.6m 54m Cash approx. $3.0m $2.0m placement @ $0.02 to issue 100
Slide 4: Executive Summary
⇝ Corticrine is a mid-stage pharmaceutical R&D company focused on development of novel treatments for Alzheimer's disease For personal use only ⇝ Corticrine is a spin-out company from Edinburgh BioQuarter, the commercialisation arm of the College of Medicine and Veterinary Executive Medicine of the
Slide 5: Alzheimer's Disease & Dementia
Healthy Alzheimer’s For personal use only Alzheimer’s Disease & Dementia ⇝ Alzheimer’s dementia is a degenerative brain Structural changes disease around loss of memory and also the loss of use and understanding of language ⇝ There is no known cure or treatment to slow progression of the disease ⇝ I
Slide 6: Alzheimer's Disease & Dementia
Alzheimer's disease (AD) commonly diagnosed in patients around 60 years of age resulting in progressive cognitive impairments (see areas affected). Alzheimer’s dementia is associated with formation of both amyloid plaques and For personal use only Alzheimer’s neurofibrillary tangles in the brain. Di
Slide 7: Market Opportunity: Dementia care vs country economies
US$ Billions For personal use only Market Opportunity Canada Mexico Turkey Dementia Sweden Indonesia Belgium If dementia care were a country, it would be the world’s 18th largest economy 7
Slide 8: Market Opportunity: Dementia care vs companies
US$ Billions For personal use only Market Opportunity Exxon Mobil Dementia Wal-Mart If dementia care were a company, it would be the world's largest by annual revenue exceeding Wal-Mart (US$476 billion) and Exxon Mobil (US$421 billion) 8
Slide 9: Market Opportunity: US patients and care costs
Americans, age 65, older Cost for care for people With Alzheimer’s disease with Alzheimer’s disease For personal use only In millions Market 13.5 million people In billions $1.08 trillion Opportunity $1,000 $800 5.1 million people $172 billion $600 $400 US is the largest market $200 ‘10 ‘15 ‘20 ‘25
Slide 10: UE2343 - 11β-HSD1 Inhibition for AD
Pre-clinical proof of concept data ⇝ 11β-HSD1 in brain is inversely associated with cognitive decline ⇝ 11β-HSD1 knockout models are protected against age-related cognitive For personal use only impairment ⇝ Small molecule inhibition of 11β-HSD1 improves cognition in ageing and UE2343 -11β-HSD1 AD m
Slide 11: Pre-Clinical Data to Date
Pre-Clinical Data to Date UE inhibitor reduces number of For personal use only Aβ plaques in AD brain Disease modifying treatment with UE inhibitor for 28 days potential of UE2343 * 6E10 positive plaques ** # of plaques per brain area Latency (sec) Cognitive Enhancement in AD with UE inhibitor Pre P
Slide 12: Human Proof of Concept
Pharmacological inhibition of HSD1with Carbenoxolone improves memory in humans For personal use only Human Proof of *Replicated in 2 cohorts Concept % change Carbenoxolone 4weeks vs placebo Completed In two randomised, double-blind, placebo- controlled crossover studies, administration of the 11β-HS
Slide 13: UE2343 Human Pharmacodynamic Data
UE2343 Pharmacodynamics Phase I study (Single Dose) For personal use only UE2343: Human Pharmacodynamic Data Average 24h Liver Inhibition Plasma ACTH * Pre-dose Plasma ACTH (pg/ml) Unary THFs / THE 23 hrs ANOVA * post-dose *p<0.01 ANOVA 80% inh *p=0.06 0 25 0 25 Dose(mg) Dose(mg) Maximal enzyme inhi
Slide 14: UE2343 Development
⇝ Synthetic process re-engineered to allow for For personal use only kilogram-scale manufacture UE 2343 ⇝ Convergent synthesis Development ⇝ Crystalline product ⇝ Attractive cost of goods UE2343 ⇝ Kilo-scale manufacture of GMP material ⇝ Simple excipient blend to allow dosing in capsules ⇝ Excellent
Slide 15: Clinical Development Steps
⇝ CTA (Clinical Trial Application) approved for multiple For personal use only ascending dose (MAD) study ⇝ PD (pharmacodynamic) biomarker validation for CNS inhibition in healthy human subjects completed Clinical Development ⇝ Phase Ib fast-fed study Steps ⇝ Phase IIa symptomatic efficacy study in
Slide 16: Clinical Development Advisory Panel
⇝ Co-founder of Corticrine Ltd ⇝ Professor of Endocrinology and Head of the University of Edinburgh/British Heart Foundation Centre for Professor Cardiovascular Science Brian Walker ⇝ Co-chair of the CORtisol NETwork (CORNET) For personal use only Clinical international consortium on cortisol resear
Slide 17: Proposed Phase I MAD Study Timetable
Participants ⇝ 20 Healthy Volunteers For personal use only Proposed Phase I Timetable ⇝ Study to commence MAD study early 2015 ⇝ Randomised double-blind crossover of placebo versus UE2343 at 3 doses ⇝ UE2343 multiple doses predicted from MAD to Intervention obtain 24 CNS exposure above administered
Slide 18: Key Investment Highlights
⇝ UE2343 was discovered in 2007 at the laboratory of Professor Brian Walker at the University of Edinburgh. Subsequently, the University received significant support from the Wellcome Trust’s Seeding Drug Discovery For personal use only program to advance UE2343 into early clinical development Key I
Slide 19: Contact Details
For personal use only Contact Details Head Office Level 2, 1 Walker Avenue, West Perth, Western Australia, 6005 Telephone: +61 (08) 9481 3860 Facsimile: +61 (08) 9321 1204 Email: [email protected]
Actinogen Medical — Merger or Acquisition (August 2014) on 6ix